Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition
| Autor: | Xavier Castells, Mercè Comas, Maria Sala, María Milagro Montero, Margarita Salvadó, Francesc Belvis, Santiago Grau, Eva Morales, Francesc Cots, Marta Riu, Juan Pablo Horcajada |
|---|---|
| Přispěvatelé: | Universitat Oberta de Catalunya (UOC) |
| Jazyk: | angličtina |
| Předmět: |
Male
Multivariate analysis Total cost Antibiotics Drug resistance resistència antimicrobiana medicine.disease_cause Antimicrobial resistance pseudomonas aeruginosa coste del hospital Economic cost Drug Resistance Multiple Bacterial Hospital Costs Aged 80 and over Cross Infection lcsh:Public aspects of medicine Health Policy Drugs Middle Aged Anti-Bacterial Agents Hospitalization Pseudomonas aeruginosa multi-drug resistance Medicamentos Costs and Cost Analysis Female hospital cost Hospital cost análisis económico resistencia a múltiples fármacos Medicaments Research Article medicine.medical_specialty medicine.drug_class cost de l'hospital economic analysis Antibiotic resistance resistència a múltiples fàrmacs Internal medicine medicine Humans Pseudomonas Infections antimicrobial resistance Intensive care medicine anàlisi econòmica Hospitals Teaching resistencia antimicrobiana Aged Retrospective Studies business.industry Economic analysis Retrospective cohort study lcsh:RA1-1270 Multi-drug resistance Spain Linear Models business |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 12, Iss 1, p 122 (2012) O2, repositorio institucional de la UOC Universitat Oberta de Catalunya (UOC) |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/1472-6963-12-122 |
| Popis: | Background We aimed to assess the hospital economic costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. Methods A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive clinical culture for P. aeruginosa more than 48 h after admission were included. Patient and hospitalization characteristics were collected from hospital and microbiology laboratory computerized records. According to antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods. Multivariate analyses were performed using generalized linear models of log-transformed costs. Results Cost estimations were available for 402 nosocomial incident P. aeruginosa positive cultures. Their distribution by antibiotic susceptibility pattern was 37.1% non-resistant, 29.6% resistant and 33.3% multi-drug resistant. The total mean economic cost per admission of patients with multi-drug resistant P. aeruginosa strains was higher than that for non-resistant strains (15,265 vs. 4,933 Euros). In multivariate analysis, resistant and multi-drug resistant strains were independently predictive of an increased hospital total cost in compared with non-resistant strains (the incremental increase in total hospital cost was more than 1.37-fold and 1.77-fold that for non-resistant strains, respectively). Conclusions P. aeruginosa multi-drug resistance independently predicted higher hospital costs with a more than 70% increase per admission compared with non-resistant strains. Prevention of the nosocomial emergence and spread of antimicrobial resistant microorganisms is essential to limit the strong economic impact. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|